BIG Breast International Group
We will find a cure for breast cancer through global research and collaboration.

BIG 2-06 ALTTO

The Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation (ALTTO) study is a randomised, multi-centre, open-label, phase III study of adjuvant lapatinib, trastuzumab, their sequence and their combination in patients with HER2/ErbB2 positive primary breast cancer.

Coordinating group: BrEAST

Patients accrual
Start date: June 2007
Closure date: July 2011
Target nr. of patients: 8400 maximum
Final accrual: 8381

Reason for closure: reached target accrual
ClinicalTrials.gov Identifier:
NCT00490139

To learn more, visit: http://alttotrials.com

Scroll to top

Contact us

Breast International Group (BIG)-aisbl Blvd de Waterloo 121 B-1000 Brussels | Belgium VAT BE 0468 176 240